在11型性的患者中,米格卢斯塔没有影响临床进展
Serena Mero1,2, Ivana Ricca1, Salvatore Rossi2,3
1Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Fondazione Stella Maris, via dei Giacinti 2, Pisa, Italy.
Neurogenetics
|December 22, 2025
概括
在患有性性11型 (SPG11) 的患者中,Miglustat被发现是安全的和耐受的,但它没有显著改善运动功能或改变关键生物标志物,这表明治疗潜力有限.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 性残11型 (SPG11) 是一种渐进的,无法治疗的神经系统疾病.
- 异常的氏体代谢与SPG11的病变产生有关.
- 临床前研究表明,miglustat可能为SPG11提供治疗益处.
研究的目的:
- 评估SPG11患者口服miglustat的短期安全性和耐受性.
- 评估miglustat对SPG11临床严重性,功能测试和生物标志物的影响.
主要方法:
- 开放标签,单中心,第二阶段研究.
- 12周口服米格卢斯塔特 (100毫克/潮4周,然后200毫克/潮8周).
- 主要结局:不良事件 (AE) 和严重不良事件 (SAE) 的发生率. 二次结果:临床评分,功能测试和生物标志物分析在3个月和6个月.
主要成果:
- 治疗 Miglustat 耐受性很好,只有轻微的副作用和没有报告的 SAE.
- 在大多数患者中,没有观察到神经运动功能的显著改善.
- 米格鲁斯塔特药物没有显著改变血脂和化物形状.
结论:
- 在SPG11患者中,Miglustat显示了可接受的短期使用安全性.
- 该药物在改善运动功能或修改相关生物标志物的有效性有限.
- 对于SPG11来说,miglustat的潜在治疗益处似乎很低.
更多相关视频
14:55Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
14.2K
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
2.9K
相关概念视频
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
01:20Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K